FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158490739> ?p ?o ?g. }

• W3158490739 endingPage "99" @default.
• W3158490739 startingPage "91" @default.
• W3158490739 abstract "<h2>Abstract</h2><h3>Background</h3> <i>KRAS</i> mutations are found in 20–25 % of non-squamous non-small cell lung cancer (NSCLC) and therapies targeting the RAS/MEK/ERK pathway are in development. We performed a multicenter open-label phase 1B trial to determine the recommended phase 2 dose and early antitumor activity of the MEK-inhibitor binimetinib combined with cisplatin and pemetrexed. <h3>Methods</h3> Eligible patients (pts) had stage III-IV NSCLC unsuitable for curative treatment, <i>KRAS</i> exon 2 or 3 (codon 12, 13 or 61) mutations, no prior systemic therapy. Pts were enrolled into part 1: 3 + 3 design with dose escalation in 2 dose levels (DL) of binimetinib and part 2: expansion cohort at the maximum tolerated dose (MTD). Pts received 4 cycles of cisplatin 75 mg/m², pemetrexed 500 mg/m²and binimetinib 30 (DL1)/45 mg (DL2) orally twice a day (bid) d1–14 q3w followed by pemetrexed and binimetinib until progressive disease (PD) or unacceptable toxicity. <h3>Results</h3> From May 2017 to Dec 2019, 18 pts (13 dose escalation, 5 expansion cohort) were enrolled. Median age was 60 (48–73, range). KRAS mutations were 87.5 % at codon 12. No DLT occurred in the dose escalation cohort. Median number of cycles was 2 (1–17, range). Treatment discontinuation was mainly due to PD (33 %) or pts/physicians' decision (27 %). Together with the expansion cohort, 16 pts were evaluable for safety. Most frequent treatment-related grade 3 AEs were lung infection (25 %), fatigue (19 %), anemia (19 %). Overall response rate among 9 evaluable pts receiving binimetinib at MTD (45 mg bid) was 33 % (7–70 %, 95 % CI). Median progression-free survival was 5.7 months (1.1−14.0, 95 % CI) and overall survival 6.5 months (1.8-NR, 95 % CI). <h3>Conclusions</h3> Pts treated with combination of cisplatin, pemetrexed and binimetinib presented no unexpected toxicity. No early signal of increased antitumor activity of binimetinib added to chemotherapy was observed in our pts population." @default.
• W3158490739 created "2021-05-10" @default.
• W3158490739 creator A5007155024 @default.
• W3158490739 creator A5008751092 @default.
• W3158490739 creator A5020553707 @default.
• W3158490739 creator A5041833929 @default.
• W3158490739 creator A5043295654 @default.
• W3158490739 creator A5044032162 @default.
• W3158490739 creator A5066360417 @default.
• W3158490739 creator A5070375776 @default.
• W3158490739 creator A5078606948 @default.
• W3158490739 creator A5080098952 @default.
• W3158490739 creator A5080595053 @default.
• W3158490739 creator A5081312940 @default.
• W3158490739 creator A5086081284 @default.
• W3158490739 creator A5091137864 @default.
• W3158490739 date "2021-06-01" @default.
• W3158490739 modified "2023-09-24" @default.
• W3158490739 title "Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial" @default.
• W3158490739 cites W1991874467 @default.
• W3158490739 cites W1994424553 @default.
• W3158490739 cites W2065477010 @default.
• W3158490739 cites W2080686146 @default.
• W3158490739 cites W2083855694 @default.
• W3158490739 cites W2094207365 @default.
• W3158490739 cites W2099725888 @default.
• W3158490739 cites W2114446999 @default.
• W3158490739 cites W2114784462 @default.
• W3158490739 cites W2118549562 @default.
• W3158490739 cites W2120203403 @default.
• W3158490739 cites W2129429534 @default.
• W3158490739 cites W2145411470 @default.
• W3158490739 cites W2165280661 @default.
• W3158490739 cites W2271051170 @default.
• W3158490739 cites W2281580962 @default.
• W3158490739 cites W2327437619 @default.
• W3158490739 cites W2405831219 @default.
• W3158490739 cites W2555901907 @default.
• W3158490739 cites W2571472603 @default.
• W3158490739 cites W2590660318 @default.
• W3158490739 cites W2611896937 @default.
• W3158490739 cites W2613467753 @default.
• W3158490739 cites W2767162493 @default.
• W3158490739 cites W2777461561 @default.
• W3158490739 cites W2793817570 @default.
• W3158490739 cites W2805354595 @default.
• W3158490739 cites W2811334006 @default.
• W3158490739 cites W2898378186 @default.
• W3158490739 cites W2906754611 @default.
• W3158490739 cites W2913235593 @default.
• W3158490739 cites W2946069134 @default.
• W3158490739 cites W2946386783 @default.
• W3158490739 cites W2946827583 @default.
• W3158490739 cites W2946878611 @default.
• W3158490739 cites W2977895282 @default.
• W3158490739 cites W2998386687 @default.
• W3158490739 cites W3010492725 @default.
• W3158490739 cites W3087229737 @default.
• W3158490739 cites W3091399767 @default.
• W3158490739 cites W4210992155 @default.
• W3158490739 doi "https://doi.org/10.1016/j.lungcan.2021.04.002" @default.
• W3158490739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33933896" @default.
• W3158490739 hasPublicationYear "2021" @default.
• W3158490739 type Work @default.
• W3158490739 sameAs 3158490739 @default.
• W3158490739 citedByCount "9" @default.
• W3158490739 countsByYear W31584907392021 @default.
• W3158490739 countsByYear W31584907392022 @default.
• W3158490739 countsByYear W31584907392023 @default.
• W3158490739 crossrefType "journal-article" @default.
• W3158490739 hasAuthorship W3158490739A5007155024 @default.
• W3158490739 hasAuthorship W3158490739A5008751092 @default.
• W3158490739 hasAuthorship W3158490739A5020553707 @default.
• W3158490739 hasAuthorship W3158490739A5041833929 @default.
• W3158490739 hasAuthorship W3158490739A5043295654 @default.
• W3158490739 hasAuthorship W3158490739A5044032162 @default.
• W3158490739 hasAuthorship W3158490739A5066360417 @default.
• W3158490739 hasAuthorship W3158490739A5070375776 @default.
• W3158490739 hasAuthorship W3158490739A5078606948 @default.
• W3158490739 hasAuthorship W3158490739A5080098952 @default.
• W3158490739 hasAuthorship W3158490739A5080595053 @default.
• W3158490739 hasAuthorship W3158490739A5081312940 @default.
• W3158490739 hasAuthorship W3158490739A5086081284 @default.
• W3158490739 hasAuthorship W3158490739A5091137864 @default.
• W3158490739 hasConcept C121608353 @default.
• W3158490739 hasConcept C126322002 @default.
• W3158490739 hasConcept C143998085 @default.
• W3158490739 hasConcept C2776256026 @default.
• W3158490739 hasConcept C2776694085 @default.
• W3158490739 hasConcept C2777240266 @default.
• W3158490739 hasConcept C2778239845 @default.
• W3158490739 hasConcept C2778715236 @default.
• W3158490739 hasConcept C2781187634 @default.
• W3158490739 hasConcept C526805850 @default.
• W3158490739 hasConcept C71924100 @default.
• W3158490739 hasConcept C72563966 @default.
• W3158490739 hasConcept C90924648 @default.
• W3158490739 hasConceptScore W3158490739C121608353 @default.

• next